Huntington's Disease
Inherited progressive neurodegenerative disorder causing movement, cognitive, and psychiatric symptoms. Cannabis has limited evidence for managing chorea, sleep, and pain in Huntington's patients; no disease-modifying effect.
- 16 states
- QUALIFYING IN
- Limited
- EVIDENCE
- G10
- ICD-10
Reviewed by Laura H. Meyer
Qualifying states
What it is
Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene. Symptoms typically appear between ages 30 and 50 and include involuntary movements (chorea), cognitive decline, psychiatric symptoms (depression, irritability, psychosis), and progressive disability over 10–20 years. Inheritance is autosomal dominant; offspring of an affected parent have a 50% risk.
There is no cure. Tetrabenazine and deutetrabenazine are FDA-approved for chorea; antidepressants and antipsychotics manage psychiatric symptoms.
Cannabis and cannabis-derived therapies
Evidence for cannabis in Huntington's disease is limited. Small clinical studies of nabilone and CBD-THC formulations have reported modest improvements in chorea and behavioral symptoms in individual patients, but trials have not consistently demonstrated benefit on validated motor or functional rating scales.
Huntington's is a qualifying condition under several state medical cannabis programs, often under broader categories such as "incurable neurodegenerative disease" or "Huntington's disease" specifically. Use should be coordinated with the patient's neurologist and HD care team.
Frequently asked questions
Does cannabis slow Huntington's disease progression?
No. There is no clinical evidence that cannabis or cannabinoids slow or modify the underlying neurodegenerative process in Huntington's disease. Cannabis use in HD is symptomatic (addressing chorea, sleep disturbance, pain, and appetite) not disease-modifying.
Is any cannabis-derived product FDA-approved for Huntington's disease?
No. No cannabis or cannabinoid medication is FDA-approved for Huntington's disease. FDA-approved chorea treatments are tetrabenazine and deutetrabenazine, which target vesicular monoamine transporter 2 (VMAT2). Unrelated to the cannabinoid system.
Which HD symptoms have the most cannabis-related evidence?
Available studies (most small and observational) describe cannabis use for chorea, sleep disturbance, pain, anxiety, and appetite stimulation. Evidence quality is limited across all symptom domains; randomized controlled trials in HD are scarce. Patients commonly combine cannabis with standard HD pharmacotherapy rather than replacing it.
What practical considerations apply when HD patients use cannabis?
HD patients often take antipsychotics, antidepressants, and chorea-control medications. All of which can interact with cannabis through cytochrome P450 metabolism and additive CNS effects. Sedation, cognitive effects, and orthostatic hypotension are heightened concerns. Caregivers should coordinate cannabis use with the neurology team, particularly during dose changes.
Sources
- NIH National Institute of Neurological Disorders and Stroke: Huntington's Diseaseaccessed May 15, 2026
- Huntington's Disease Society of Americaaccessed May 15, 2026